Asia-Pacific is expected to grow at the fastest CAGR during 2025-2034
At its highest dose, 36 mg, participants in a phase 3 trial lost an average of 12.4 percent of their starting weight over 72 weeks
Kim GL, Song JG, Han HK
Food and Drug Administration (FDA) approving semaglutide (Wegovy) pills for weight management, a pill option is now available with more approvals potentially to come
In 2025, the company delivered a solid +8.56% YoY revenue growth, driven by its immunology portfolio: Skyrizi ($17.56B) continues to surge with strong uptake across psoriasis and IBD, Rinvoq ($8.3B) is expanding rapidly across multiple inflammatory conditions, while Humira ($4.54B) continues to decline following loss of exclusivity marking a clear shift toward newer growth assets
Diarrhea is one of the most frequently reported side effects of semaglutide, a GLP-1 receptor agonist used to treat type 2 diabetes and support chronic weight management